英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Orionis查看　Orionis　在百度字典中的解释百度英翻中〔查看〕
Orionis查看　Orionis　在Google字典中的解释Google英翻中〔查看〕
Orionis查看　Orionis　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Biotechnology Solutions | Orionis Biosciences
    Orionis is a clinical-stage life sciences company pioneering the development of novel precision medicines Our drug modalities – including molecular glues, cytokines, and cell engagers – harness the body’s natural defense mechanisms to fight cancer more effectively
  • About Us | Company Overview by Orionis Biosciences
    Visit the About Us section of Orionis Biosciences Understand our vision and dedication to pioneering biosciences
  • Orionis Biosciences Announces Strategic Partnership with Genentech to . . .
    Orionis to receive $105 million upfront, as well as future milestone-related payments Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovalent glues May 21st, 2025, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced
  • Pipeline | Drug Development by Orionis Biosciences
    Discover our innovative Drug Development at Orionis Biosciences Learn about our latest research and progress
  • Platforms | Biotechnology at Orionis Biosciences
    Orionis has developed three transformative technology platforms While technologically distinct, addressing small and large molecules, they all harness proximity and cooperativity mechanisms in drug mode of action These innovations are leveraged to create precision medicines that engage with, modulate or dispose of disease targets with a high degree of selectivity, limiting off-target
  • Orionis Biosciences Announces Collaboration with Genentech to Discover . . .
    Orionis to receive $47 million upfront, as well as future milestone-related payments Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year
  • News | Biotechnology News by Orionis Biosciences
    Discover the latest Biotechnology News from Orionis Biosciences Stay updated on our innovations and breakthroughs
  • Contact | Collaboration Opportunities by Orionis Biosciences
    Discover collaboration opportunities with Orionis Biosciences Explore our platforms and strategic partnerships
  • Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical . . .
    November 15, 2023, BOSTON, MA, and GHENT, Belgium – Orionis Biosciences, a life sciences company pioneering the creation of highly selective and tunable therapeutics for cancer and other diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of ORB-011, an attenuated, cis-targeted interferon immunotherapy
  • Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 . . .
    Boston, MA Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein Antibody Engineering Summit, taking place November 14 – 16 in





中文字典-英文字典  2005-2009